ARCA biopharma Company Profile (NASDAQ:ABIO)

Analyst Ratings

Consensus Ratings for ARCA biopharma (NASDAQ:ABIO) (?)
Ratings Breakdown: 2 Hold Rating(s)
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: $4.00 (33.83% upside)

Analysts' Ratings History for ARCA biopharma (NASDAQ:ABIO)
Show:
DateFirmActionRatingPrice TargetActions
2/23/2016Royal Bank Of CanadaReiterated RatingSector Perform$5.00 -> $4.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/23/2016Cowen and CompanyReiterated RatingMarket Perform$5.50 -> $4.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/24/2014 forward)

Earnings

Earnings History for ARCA biopharma (NASDAQ:ABIO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/9/2016        
11/21/2014($0.15)($0.11)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/19/2014($0.13)($0.11)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/29/2014($0.12)($0.13)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for ARCA biopharma (NASDAQ:ABIO)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for ARCA biopharma (NASDAQ:ABIO)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for ARCA biopharma (NASDAQ:ABIO)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
4/5/2016Christopher David OzeroffVPSell366$3.52$1,288.32View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/5/2016Michael R BristowInsiderSell724$3.52$2,548.48View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/5/2016Thomas A KeuerCOOSell384$3.52$1,351.68View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/4/2016Brian L SelbyVPSell1,114$3.52$3,921.28View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/1/2016Christopher David OzeroffVPSell458$3.51$1,607.58View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/1/2016Michael R. BristowInsiderSell752$3.50$2,632.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/1/2016Thomas A. KeuerCOOSell457$3.53$1,613.21View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/18/2015Christopher David OzeroffVPSell1,129$6.32$7,135.28View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/2/2015Brian L SelbyVPSell1,125$0.71$798.75View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/2/2015Michael R BristowInsiderSell5,446$0.71$3,866.66View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/16/2015Riley MccormackMajor ShareholderSell350,000$0.76$266,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/7/2015Riley MccormackMajor ShareholderSell550,000$0.92$506,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/18/2014Michael R BristowCEOSell13,853$1.30$18,008.90View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/18/2014Patrick M WheelerCFOSell8,246$1.31$10,802.26View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/4/2014Riley MccormackMajor ShareholderBuy1,000,000$1.70$1,700,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for ARCA biopharma (NASDAQ:ABIO)
DateHeadline
06/15/16 02:16 PMForm 4 ARCA biopharma, Inc. For: Jun 09 Filed by: Selby Brian L.
06/15/16 02:16 PMARCA BIOPHARMA, INC. : Change in Directors or Principal Officers, Submission of Matters to a Vote of Security Holders (form 8-K)
06/13/16 04:01 PMARCA BIOPHARMA, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a Vote o -
05/12/16 08:47 AMARCA biopharma Announces First Quarter 2016 Financial Results and Provides Business Update - Business Wire (press release) - ARCA biopharma Announces First Quarter 2016 Financial Results and Provides Business UpdateBusiness Wire (press release)BUSINESS WIRE)--ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today reported financial results for the quarter ended March 31, 2016, and provided a business ...and more »
05/11/16 06:07 PMARCA biopharma Announces First Quarter 2016 Financial Results and Provides Business Update - [at noodls] - ARCA biopharma Announces First Quarter 2016 Financial Results and Provides Business Update
05/11/16 03:49 PMARCA BIOPHARMA, INC. Files SEC form 10-Q, Quarterly Report -
05/08/16 07:44 AMARCA Biopharma, Inc. (ABIO) Broker Price Targets For The Coming Week - Share Trading News - ARCA Biopharma, Inc. (ABIO) Broker Price Targets For The Coming WeekShare Trading NewsMarket analysts have recently updated their ratings and price targets on shares of ARCA biopharma, Inc. (ABIO). The latest reports which are currently in issue on Sunday 8th of May state 0 analysts have a rating of “strong buy”, 0 analysts “buy”, 0 ...
05/05/16 08:16 AMBroker Roundup For ARCA Biopharma, Inc. (ABIO) - Share Trading News - Broker Roundup For ARCA Biopharma, Inc. (ABIO)Share Trading NewsThe share price of ARCA biopharma, Inc. (ABIO) was up +0.00% during the last trading session, with a day high of 4.13. 34874 shares were traded on ARCA biopharma, Inc.'s last session. The stock's 50 day moving average is 3.71 and its 200 day moving ...
04/28/16 08:30 AMLatest Analyst Ratings For ARCA Biopharma, Inc. (ABIO) - Share Trading News - Latest Analyst Ratings For ARCA Biopharma, Inc. (ABIO)Share Trading NewsARCA biopharma, Inc. has a 50 day moving average of 3.66 and a 200 day moving average of 4.36. The stock's market capitalization is 36.66M, it has a 52-week low of 3.05 and a 52-week high of 10.85. The share price of the company (ABIO) was down ...
04/27/16 09:51 AMArca Biopharma Inc (NASDAQ:ABIO)'s Company Shares Increased 0.28% After Low Volatility - CCH Daily News - Arca Biopharma Inc (NASDAQ:ABIO)'s Company Shares Increased 0.28% After Low VolatilityCCH Daily NewsThe shares of Arca Biopharma Inc (NASDAQ:ABIO) increased by 0.28% in the last 20 days but lost 2.94% in the past 5 trading sessions. Arca Biopharma Inc (NASDAQ:ABIO) shares opened at $3.52 in the last session and had intraday high of $3.66 and low of ...Arca Biopharma Incorporated (NASDAQ:ABIO) Short Interest Decreased By 10.89%The PostList To Watch: Gilead Sciences (NASDAQ:GILD), ARCA biopharma (NASDAQ:ABIO), Advanced Semiconductor ...Gaining Green (press release) (registration) (blog)all 4 news articles »
04/27/16 09:51 AMNext Weeks Broker Price Targets For ARCA Biopharma, Inc. (ABIO) - Share Trading News - Next Weeks Broker Price Targets For ARCA Biopharma, Inc. (ABIO)Share Trading News02/23/2016 – ARCA biopharma, Inc. had its “sector perform” rating reiterated by analysts at RBC Capital. They now have a USD 4 price target on the stock. 02/23/2016 – ARCA biopharma, Inc. had its “market perform” rating reiterated by analysts at Cowen.What's in Arca Biopharma Inc After Forming Multiple Bottom?The Postall 2 news articles »
04/26/16 09:20 AMInvestors Watch List: ARCA biopharma, Inc. (NASDAQ:ABIO), Idera Pharmaceuticals (NASDAQ:IDRA), EverBank ... - KC Register - Investors Watch List: ARCA biopharma, Inc. (NASDAQ:ABIO), Idera Pharmaceuticals (NASDAQ:IDRA), EverBank ...KC RegisterOn April 18, ARCA biopharma, Inc. (NASDAQ:ABIO) announced that the 75th patient has been enrolled in GENETIC-AF, a Phase 2B/3 clinical trial evaluating Gencaro as a potential treatment for atrial fibrillation. Seventy-five patients enrolled is the ...
04/26/16 09:20 AMWhat's in Arca Biopharma Inc After Forming Multiple Bottom? - The Post - What's in Arca Biopharma Inc After Forming Multiple Bottom?The PostThe stock of Arca Biopharma Inc (ABIO) shows a multiple bottoms pattern with $3.49 target or 13.00% below today's $4.01 share price. The 6 months chart pattern indicates high risk for the $41.72 million company. It was reported on Apr, 26 by Finviz.com.Arca Biopharma Inc (NASDAQ:ABIO)'s Company Shares Increased 0.28% After Low VolatilityCCH Daily NewsList To Watch: Gilead Sciences (NASDAQ:GILD), ARCA biopharma (NASDAQ:ABIO), Advanced Semiconductor ...Gaining Green (press release) (registration) (blog)all 4 news articles »
04/26/16 09:20 AMPipeline of congestive heart failure (heart failure) market H1 2016published by leading research firm - Inc., Angion Biomedica Corp., ARCA biopharma, Inc., Ascelegen Therapeutics, Inc., Asklepios BioPharmaceutical, Inc., Asterias Biotherapeutics, Inc., Athersys, Inc., Bayer AG, BEAT BioTherapeutics Corp., BioCardia, Inc., Bristol-Myers Squibb Company ...
04/26/16 09:20 AMArca Biopharma Incorporated (NASDAQ:ABIO) Short Interest Decreased By 10.89% - The stock decreased 1.39% or $0.05 on April 22, hitting $3.55. About 3,869 shares traded hands. Arca Biopharma Inc (NASDAQ:ABIO) has declined 43.28% since September 17, 2015 and is downtrending. It has underperformed by 48.38% the S&P500. ARCA biopharma ...
04/21/16 09:25 AMARCA Biopharma, Inc. (ABIO) Latest Broker Views - Risers & Fallers - ARCA Biopharma, Inc. (ABIO) Latest Broker ViewsRisers & FallersA number of investment brokers have recently updated their price targets on shares of ARCA biopharma, Inc. (ABIO). According to the latest broker reports outstanding on Wednesday 20th of April, 0 analysts have a rating of “strong buy”, 0 analysts “buy ...
04/18/16 03:31 PMARCA BIOPHARMA, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits -
04/18/16 09:27 AMARCA biopharma Announces 75th Patient Enrolled in GENETIC-AF Phase 2B/3 Clinical Trial - Business Wire (press release) - ARCA biopharma Announces 75th Patient Enrolled in GENETIC-AF Phase 2B/3 Clinical TrialBusiness Wire (press release)WESTMINSTER, Colo.--(BUSINESS WIRE)--ARCA biopharma, Inc. (Nasdaq:ABIO), a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced that the 75th patient has been enrolled in ...and more »
04/18/16 08:00 AMARCA biopharma Announces 75th Patient Enrolled in GENETIC-AF Phase 2B/3 Clinical Trial - [Business Wire] - ARCA biopharma, Inc. , a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced that the 75th patient has been enrolled in GENETIC-AF, a Phase 2B/3 clinical trial evaluating Gencaro as a potential treatment for atrial fibrillation.
04/15/16 12:22 PMArca Biopharma Incorporated (NASDAQ:ABIO) Shorted Shares Decreased By 10.89% - Stock Caller - Arca Biopharma Incorporated (NASDAQ:ABIO) Shorted Shares Decreased By 10.89%Stock CallerWith 15,300 shares average volume, it will take short sellers 13 days to cover their ABIO's short positions. The short interest to Arca Biopharma Incorporated's float is 4.44%. The stock increased 8.16% or $0.28 on April 14, hitting $3.71. Arca ...and more »
04/12/16 12:18 PMAnalyst Coverage: ARCA Biopharma, Inc. (ABIO) - Risers & Fallers - Analyst Coverage: ARCA Biopharma, Inc. (ABIO)Risers & FallersRecently stock market analysts have updated their consensus ratings on shares of ARCA biopharma, Inc. (ABIO). The latest broker reports which are currently outstanding on Tuesday 12th of April state 0 analysts have a rating of “strong buy”, 1 analysts ...
04/08/16 12:29 PMRa Capital Management Lowers stake in Arca Biopharma Inc (ABIO) - The Sussex Pilot - Ra Capital Management Lowers stake in Arca Biopharma Inc (ABIO)The Sussex PilotArca Biopharma Inc (ABIO) : Ra Capital Management reduced its stake in Arca Biopharma Inc by 4.07% during the Q4 period. The investment management company now holds a total of 778,211 shares of Arca Biopharma Inc which is valued at $2.9 Million ...
04/07/16 12:48 PMWatch for Action: BGC Partners (NASDAQ:BGCP), ARCA biopharma (NASDAQ:ABIO), Vale S.A. (NYSE:VALE ... - Property Mentor - Watch for Action: BGC Partners (NASDAQ:BGCP), ARCA biopharma (NASDAQ:ABIO), Vale S.A. (NYSE:VALE ...Property MentorARCA biopharma, Inc. (NASDAQ:ABIO) said that, GENETIC-AF is a Phase 2B/Phase 3, multi-center, randomized, double-blind, adaptive design clinical trial comparing the safety and efficacy of Gencaro to Toprol-XL (metoprolol succinate) for the treatment of ...and more »
04/07/16 12:48 PMArca Biopharma, Inc. (ABIO) Files Form 4 Insider Selling : Thomas A Keuer Sells 384 Shares - SCSUCollegian - Arca Biopharma, Inc. (ABIO) Files Form 4 Insider Selling : Thomas A Keuer Sells 384 SharesSCSUCollegianArca Biopharma, Inc. Executive reported Insider selling to the SEC on Apr 6, 2016 in a Form 4 Filing. Thomas A Keuer , Chief Operating Officer of Arca Biopharma, Inc. sold 384 shares on Apr 5, 2016. The shares were sold at $3.52 per share for a total ...and more »
04/05/16 01:52 PMBroker Changes For ARCA Biopharma, Inc. (ABIO) - Risers & Fallers - Broker Changes For ARCA Biopharma, Inc. (ABIO)Risers & FallersRecently stock market analysts have updated their consensus ratings on shares of ARCA biopharma, Inc. (ABIO). The latest broker reports which are currently outstanding on Tuesday 5th of April state 0 analysts have a rating of “strong buy”, 1 analysts ...
04/03/16 01:35 PMAfter Last Week What Do Analysts Think Of ARCA Biopharma, Inc. (ABIO) - Share Trading News - After Last Week What Do Analysts Think Of ARCA Biopharma, Inc. (ABIO)Share Trading NewsRecently some investment brokers have made changes to their outstanding price targets on shares of ARCA biopharma, Inc. (ABIO). According to data from Reuters, 0 analysts have a rating of “buy”, 1 analysts “outperform”, 0 analysts “hold”, 0 analysts ...and more »
04/02/16 12:30 PMArray Bio ends late-stage study of ovarian cancer drug - ETHealthWorld.com - ETHealthWorld.comArray Bio ends late-stage study of ovarian cancer drugETHealthWorld.comArray BioPharma Inc said it was abandoning a late-stage study testing its experimental ovarian cancer drug, after an interim analysis showed the trial would likely fail. The drugmaker said on Friday that the other studies of binimetinib, its lead drug ...and more »
04/02/16 12:30 PMARCA Biopharma, Inc. (ABIO) Analyst Review - Risers & Fallers - ARCA Biopharma, Inc. (ABIO) Analyst ReviewRisers & FallersA number of investment brokers have recently updated their price targets on shares of ARCA biopharma, Inc. (ABIO). According to the latest broker reports outstanding on Thursday 31st of March, 0 analysts have a rating of “strong buy”, 1 analysts “buy”, ...
04/02/16 12:30 PMAtrial fibrillation 2016 market pipeline review research made available by top research firm - Companies Involved in Therapeutics Development ARCA biopharma, Inc., AstraZeneca Plc, Bristol-Myers Squibb Company, Cardiome Pharma Corp., Daiichi Sankyo Company, Limited, Gilead Sciences, Inc., Ionis Pharmaceuticals, Inc., Laboratoires Pierre Fabre SA ...
03/30/16 01:39 PMNRPB & Pharma Innovation Partnerships 2015 -- Highlights - SYS-CON Media (press release) - NRPB & Pharma Innovation Partnerships 2015 -- HighlightsSYS-CON Media (press release)TAIPEI, TAIWAN -- (Marketwired) -- 03/30/16 -- BioBusiness Asia 2015 (BBA) kicked off a series of events and seminars that offered a perspective in Precision Medicine, Bio-ICT, IP strategies and explored global market trends, strategies with big pharma ...and more »
03/30/16 01:39 PMVhcp Management Lowers stake in Arca Biopharma Inc (ABIO) - Los Angeles Mirror - Vhcp Management Lowers stake in Arca Biopharma Inc (ABIO)Los Angeles MirrorArca Biopharma Inc (ABIO) : Vhcp Management reduced its stake in Arca Biopharma Inc by 70.0% during the Q4 period. The investment management company now holds a total of 462,399 shares of Arca Biopharma Inc which is valued at $1.7 Million after ...This Weeks Broker Price Targets For ARCA Biopharma, Inc. (ABIO)Share Trading Newsall 1 news articles »
03/26/16 01:27 PMIn Focus Stocks: ARCA biopharma (NASDAQ:ABIO), Advanced Energy Industries (NASDAQ:AEIS), Shell Midstream ... - Property Mentor - In Focus Stocks: ARCA biopharma (NASDAQ:ABIO), Advanced Energy Industries (NASDAQ:AEIS), Shell Midstream ...Property MentorMiller Industries Inc. (NYSE:MLR) shares moved down -3.02% in last trading session and ended the day at $19.28. MLR Gross Margin is 10.60% and its has a return on assets of 5.90%. Miller Industries Inc. (NYSE:MLR) quarterly performance is -7.00%.and more »
03/26/16 01:27 PMAnalyst Coverage Updates - ARCA Biopharma, Inc. (ABIO) - Risers & Fallers - Analyst Coverage Updates - ARCA Biopharma, Inc. (ABIO)Risers & FallersRecently stock market analysts have updated their consensus ratings on shares of ARCA biopharma, Inc. (ABIO). The latest broker reports which are currently outstanding on Thursday 24th of March state 0 analysts have a rating of “strong buy”, 1 analysts ...
03/23/16 12:04 PMARCA BIOPHARMA, INC. Financials -
03/20/16 01:51 PMAfter Last Week What Do Analysts Think Of ARCA Biopharma, Inc. (ABIO)? - Risers & Fallers - After Last Week What Do Analysts Think Of ARCA Biopharma, Inc. (ABIO)?Risers & FallersA number of investment brokers have recently updated their price targets on shares of ARCA biopharma, Inc. (ABIO). According to the latest broker reports 0 analysts have a rating of “buy”, 1 analysts “outperform”, 0 analysts “hold”, 0 analysts ...
03/19/16 11:56 AMTTHI, HBIO Put On Notice, Elite Gets FDA Date, VYGR Gets Ready To Sail - Nasdaq - TTHI, HBIO Put On Notice, Elite Gets FDA Date, VYGR Gets Ready To SailNasdaq(RTTNews.com) - ARCA biopharma Inc.'s ( ABIO ) phase IIb/phase III clinical trial comparing the safety and efficacy of Gencaro to Toprol-XL for the treatment of atrial fibrillation is underway. The company expects outcome of interim analysis of phase ...and more »
03/17/16 05:20 PM6:20 pm ARCA biopharma reports FY15 EPS of ($1.82) vs. ($3.31) a year ago, provides corporate update -
03/17/16 03:44 PMARCA BIOPHARMA, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhi -
03/17/16 03:30 PMARCA biopharma Announces Fiscal Year 2015 Financial Results and Provides Business Update - [Business Wire] - ARCA biopharma, Inc. , a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today reported financial results for the year ended December 31, 2015, and provided a business update.
03/17/16 03:14 PMARCA BIOPHARMA, INC. Files SEC form 10-K, Annual Report -
03/17/16 01:25 PMBearish case for Valeant -
03/17/16 01:17 PMARCA Biopharma, Inc. (ABIO) Updated Price Targets - Share Trading News - ARCA Biopharma, Inc. (ABIO) Updated Price TargetsShare Trading NewsRecently analysts working for a variety of stock market brokerages have changed their consensus ratings and price targets on shares of ARCA biopharma, Inc. (ABIO). The most recent broker reports which have been released note that 0 analysts have a ...
03/07/16 03:32 PMARCA BIOPHARMA, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibit -
03/01/16 01:53 PMChanges To Broker Targets On ARCA Biopharma, Inc. (ABIO) - Share Trading News - Changes To Broker Targets On ARCA Biopharma, Inc. (ABIO)Share Trading News10/09/2013 – Dawson James began new coverage on ARCA biopharma, Inc. giving the company a “buy” rating. They now have a USD 3.75 price target on the stock. The share price of ARCA biopharma, Inc. (ABIO) was down -5.23% during the last trading ...
02/29/16 01:36 PMScorching Hot Biotech Tape - Intrexon Corp. (XON), Array BioPharma Inc. (ARRY), Alexion Pharmaceuticals, Inc. (ALXN) - iStreetWire - Scorching Hot Biotech Tape - Intrexon Corp. (XON), Array BioPharma Inc. (ARRY), Alexion Pharmaceuticals, Inc. (ALXN)iStreetWireIntrexon Corporation (NYSE:XON) rose +7.00% to $33.76. Intrexon Corporation (NYSE:XON) on February 25, 2016, announced it has agreed to acquire the business of EnviroFlight LLC and form a joint venture with Darling Ingredients Inc. (DAR), the world's ...and more »
02/26/16 07:12 AMARCA biopharma, Inc. (ABIO) - ARCA biopharma, Inc., a biopharmaceutical company, focuses on developing genetically-targeted therapies for cardiovascular diseases. Its lead product candidate is Gencaro, a pharmacologically unique beta-blocker and mild vasodilator for the treatment of ...
02/19/16 12:27 PMNew Price Targets On ARCA Biopharma, Inc. (ABIO) - Risers & Fallers - New Price Targets On ARCA Biopharma, Inc. (ABIO)Risers & FallersRecently stock market analysts have updated their consensus ratings on shares of ARCA biopharma, Inc. (ABIO). The latest broker reports which are currently outstanding on Friday 19th of February state 0 analysts have a rating of “strong buy”, 1 ...
01/12/16 07:30 AMGENETIC-AF Clinical Trial for Prevention of Atrial Fibrillation Enrolls 50th Patient - [Business Wire] - ARCA biopharma, Inc. , a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today provided an update on GENETIC-AF, the Company’s Phase 2B/3 clinical trial evaluating GencaroTM as a potential genetically-targeted treatment for the prevention of atrial fibrillation.
12/08/15 08:00 AMApplying Lessons from KBIO - [Accesswire] - LAS VEGAS, NV / ACCESSWIRE / December 8, 2015 / KaleBios Pharmaceuticals shares have gained 1,279% this month. KaloBios has been surging since Shkreli bought a 70% stake in the company, rescuing it from ...
11/30/15 08:38 AM2 Micro-Cap Opportunities in Atrial Fibrillation - [Accesswire] - REDONDO BEACH, CA / ACCESSWIRE / November 30, 2015 / Atrial fibrillation - or A-fib - is the most common cardiac arrhythmia, affecting roughly five million Americans, according to the American Journal ...

Social

About ARCA biopharma

ARCA biopharma, Inc. (ARCA) is a biopharmaceutical company. The Company is principally focused on developing genetically-targeted therapies for cardiovascular diseases. The Company's lead product candidate is Gencaro (bucindolol hydrochloride), a beta-blocker and mild vasodilator that the Company is evaluating in a clinical trial for the treatment of atrial fibrillation (AF) in patients with heart failure with reduced left ventricular ejection fraction (HFREF). Gencaro is considered part of the beta-blocker class of compounds because of its property of blocking both beta-1 and beta-2, receptors in the heart. The blocking of these receptors prevents the receptor from binding with other molecules, primarily the neurotransmitter norepinephrine (NE), which activate these receptors. The Company is conducting a Phase IIB/III clinical trial of Gencaro, known as GENETIC-AF.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: ABIO
  • CUSIP:
Key Metrics:
  • Previous Close: $2.99
  • 50 Day Moving Average: $3.0554
  • 200 Day Moving Average: $3.5254
  • P/E Ratio: N/A
  • P/E Growth: 0.0000
  • Market Cap: $27.10M
  • Beta: 1.57
Additional Links:
ARCA biopharma (NASDAQ:ABIO) Chart for Sunday, July, 24, 2016